Real-world data of durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer: A Thailand multicenter observational study

被引：0
|
作者：
Tanasanvimon, Suebpong
Maneenil, Kunlatida
Wirasorn, Kosin
Thanasombunsukh, Kijjakom
Korphaisarn, Krittiya
Sathitruangsak, Chirawadee
Wanchaijiraboon, Passakorn
Siripoon, Teerada
Teeyapan, Nattaya
Charonpongsuntorn, Chanchai
Suksombooncharoen, Thatthan
Thambamroong, Tawasapon
Laosuangkoon, Wannisa
Ngokngarm, Chavapon
Simseekeaw, Pronwasun
Akewanlop, Charuwan
Sirachainan, Ekaphop
TSCO GI Grp
机构：
[1] Chulalongkorn Univ, King Chulalongkorn Mem Hosp, Thai Red Cross Soc, Dept Internal Med,Fac Med, Bangkok, Thailand
[2] Rajavithi Hosp, Bangkok, Thailand
[3] Khon Kaen Univ, Fac Med, Mueang Khon Kaen, Thailand
[4] Minist Publ Hlth, Lampang Hosp, Lampang, Thailand
[5] Siriraj Hosp, Bangkok Noi, Thailand
[6] Prince Songkla Univ, Hat Yai, Thailand
[7] Phrapokklao Hosp, Phrapokklao Canc Ctr Excellence, Chanthaburi, Thailand
[8] Mahidol Univ, Ramathibodi Hosp, Ratchathewi, Thailand
[9] King Chulalongkorn Mem Hosp, Bangkok, Thailand
[10] Srinakharinwirot Univ, Fac Med, Dept Internal Med, Nakhon Nayok, Thailand
[11] Chiang Mai Univ, Mueang Chiang Mai, Thailand
[12] Phramongkutklao Coll Med, Bangkok, Thailand
[13] Udon Thani Hosp, Udon Thani, Thailand
[14] Queen Savang Vadhana Mem Hosp, Si Racha, Thailand
[15] Minist Publ Hlth, Sakon Nakhon Hosp, Bangkok, Thailand
[16] Mahidol Univ, Fac Med, Dept Med, Div Med Oncol,Siriraj Hosp, Bangkok, Thailand
[17] Ramathibodi Hosp, Dept Med, Fac Med, Ratchathewi, Thailand
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.607
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：607 / 607
页数：1
相关论文
共 50 条
  • [21] Gemcitabine Plus Cisplatin Versus Gemcitabine Chemotherapy for Advanced Biliary Tract Cancer
    Park, Jin Myung
    Ryu, Ji Kon
    Paik, Woo Hyun
    Song, Byeong Jun
    Park, Joo Kyung
    Kim, Yong-Tae
    Yoon, Yong Bum
    GASTROENTEROLOGY, 2013, 144 (05) : S529 - S529
  • [22] Initial Use Experience of Durvalumab Plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer in a Japanese Territory Center
    Shionoya, Kento
    Sofuni, Atsushi
    Mukai, Shuntaro
    Yamauchi, Yoshiya
    Tsuchiya, Takayoshi
    Tanaka, Reina
    Tonozuka, Ryosuke
    Yamamoto, Kenjiro
    Nagai, Kazumasa
    Matsunami, Yukitoshi
    Kojima, Hiroyuki
    Minami, Hirohito
    Hirakawa, Noriyuki
    Zhan, Qiang
    Itoi, Takao
    CANCERS, 2025, 17 (02)
  • [23] Efficacy and safety of durvalumab plus tremelimumab for unresectable hepatocellular carcinoma in Thailand: A real-world multicenter observational study.
    Korphaisarn, Krittiya
    Wirasorn, Kosin
    Tanasanvimon, Suebpong
    Thanasombunsukh, Kijjakom
    Maneenil, Kunlatida
    Thanestada, Jirawat
    Teeyapun, Nattaya
    Chindaprasirt, Jarin
    Sathitruangsak, Chirawadee
    Siripoon, Teerada
    Tiraswasdichai, Phannin
    Charonpongsuntorn, Chanchai
    Wanchaijiraboon, Passakorn
    Laosuangkoon, Wannisa
    Sunpaweravong, Patrapim
    Akewanlop, Charuwan
    TSCO GI Groups
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 539 - 539
  • [24] Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
    Park, Joon Oh
    Oh, Do-Youn
    Hsu, Chiun
    Chen, Jen-Shi
    Chen, Li-Tzong
    Orlando, Mauro
    Kim, Jong Seok
    Lim, Ho Yeong
    CANCER RESEARCH AND TREATMENT, 2015, 47 (03): : 343 - 361
  • [25] Cisplatin plus Gemcitabine for Biliary Tract Cancer
    Cariati, Andrea
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (02): : 192 - 192
  • [26] Gemcitabine and cisplatin plus immunotherapy in advanced biliary tract cancer: a phase II study
    不详
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2022, 19 (5) : 280 - 280
  • [27] Gemcitabine and cisplatin plus immunotherapy in advanced biliary tract cancer: a phase II study
    Jordan Hindson
    Nature Reviews Gastroenterology & Hepatology, 2022, 19 : 280 - 280
  • [28] Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience
    Chiao-En Wu
    Wen-Chi Chou
    Chia-Hsun Hsieh
    John Wen-Cheng Chang
    Cheng-Yu Lin
    Chun-Nan Yeh
    Jen-Shi Chen
    BMC Cancer, 20
  • [29] Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience
    Wu, Chiao-En
    Chou, Wen-Chi
    Hsieh, Chia-Hsun
    Chang, John Wen-Cheng
    Lin, Cheng-Yu
    Yeh, Chun-Nan
    Chen, Jen-Shi
    BMC CANCER, 2020, 20 (01)
  • [30] Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort
    Mitzlaff, Katharina
    Kirstein, Martha M.
    Mueller, Christian
    Venerito, Marino
    Olkus, Alexander
    Dill, Michael T.
    Weinmann, Arndt
    Kocheise, Lorenz
    Busch, Alina
    Schulze, Kornelius
    Allo, Gabriel
    Waldschmidt, Dirk-Thomas
    Barsch, Maryam
    Bengsch, Bertram
    Quante, Michael
    Gonzalez-Carmona, Maria A.
    Himmelsbach, Vera
    Finkelmeier, Fabian
    Kloeckner, Roman
    Schirmacher, Peter
    Marquardt, Jens U.
    Zimpel, Carolin
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2024, 12 (09) : 1230 - 1242
12345